Nothing Special   »   [go: up one dir, main page]

AR013462A1 - Nuevos peptidomimeticos para el tratamiento de trastornos oseos, metodos para su produccion y drogas que contienen estos compuestos - Google Patents

Nuevos peptidomimeticos para el tratamiento de trastornos oseos, metodos para su produccion y drogas que contienen estos compuestos

Info

Publication number
AR013462A1
AR013462A1 ARP980104401A ARP980104401A AR013462A1 AR 013462 A1 AR013462 A1 AR 013462A1 AR P980104401 A ARP980104401 A AR P980104401A AR P980104401 A ARP980104401 A AR P980104401A AR 013462 A1 AR013462 A1 AR 013462A1
Authority
AR
Argentina
Prior art keywords
compounds
contain
production
amino acid
peptidomimeticos
Prior art date
Application number
ARP980104401A
Other languages
English (en)
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Publication of AR013462A1 publication Critical patent/AR013462A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Compuestos de la formula general (I), en donde: R1, R2, R3 y X pueden ser iguales o diferentes, y en donde R1, R2 representan hidrogeno, un residuoarilo, alquilo, peptidilo o aminoácido; R3 representa un residuo -NR31R32, hidroxi o alcoxi inferior, en donde R31, R32 representan independientementehidrogeno, un residuo arilo, alquilo, peptidilo o aminoácido; X representa un aminoácido o un péptido; R4 representa hidrogeno, hidroxi, amino oalquilo C1-4; m repesenta un numero entre 0 y 5; R5 repesenta una mitad mono- o bicíclica saturada o insaturada opcionalmente sustituida que puedecontener uno o más heteroátomos, un grupo alquilo C1-11 que puede tener sustituciones o heteroátomos intermitentes, sus tautomeros, isomeros,prodrogas y sales farmacéuticamente aceptables, así como también su produccion y su uso como medicamentos.
ARP980104401A 1997-09-05 1998-09-03 Nuevos peptidomimeticos para el tratamiento de trastornos oseos, metodos para su produccion y drogas que contienen estos compuestos AR013462A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97115402A EP0902036A1 (en) 1997-09-05 1997-09-05 Peptide containing an arginine mimetic for the treatment of osteoporosis, their production, and drugs containing these compounds

Publications (1)

Publication Number Publication Date
AR013462A1 true AR013462A1 (es) 2000-12-27

Family

ID=8227319

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980104401A AR013462A1 (es) 1997-09-05 1998-09-03 Nuevos peptidomimeticos para el tratamiento de trastornos oseos, metodos para su produccion y drogas que contienen estos compuestos

Country Status (12)

Country Link
US (1) US6429288B1 (es)
EP (2) EP0902036A1 (es)
JP (1) JP2001515919A (es)
KR (1) KR20010023656A (es)
CN (1) CN1269806A (es)
AR (1) AR013462A1 (es)
AU (1) AU9439398A (es)
BR (1) BR9812056A (es)
CA (1) CA2301969A1 (es)
TR (1) TR200000598T2 (es)
WO (1) WO1999012970A1 (es)
ZA (1) ZA988095B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0115079A (pt) * 2000-10-30 2003-08-19 Warner Lambert Co Ligandos do receptor de serotonina à base de amidino-uréia e composições destes, seus usos farmacêuticos e métodos para a suas sìnteses
US6946562B2 (en) * 2001-12-12 2005-09-20 Eastman Kodak Company Synthesis of peptoid substituted azole compounds
US8775112B2 (en) 2003-09-15 2014-07-08 Nvidia Corporation System and method for increasing die yield
US8732644B1 (en) 2003-09-15 2014-05-20 Nvidia Corporation Micro electro mechanical switch system and method for testing and configuring semiconductor functional circuits
US8775997B2 (en) 2003-09-15 2014-07-08 Nvidia Corporation System and method for testing and configuring semiconductor functional circuits
US8711161B1 (en) 2003-12-18 2014-04-29 Nvidia Corporation Functional component compensation reconfiguration system and method
US8723231B1 (en) 2004-09-15 2014-05-13 Nvidia Corporation Semiconductor die micro electro-mechanical switch management system and method
US8711156B1 (en) 2004-09-30 2014-04-29 Nvidia Corporation Method and system for remapping processing elements in a pipeline of a graphics processing unit
US8021193B1 (en) * 2005-04-25 2011-09-20 Nvidia Corporation Controlled impedance display adapter
US7793029B1 (en) 2005-05-17 2010-09-07 Nvidia Corporation Translation device apparatus for configuring printed circuit board connectors
US8417838B2 (en) * 2005-12-12 2013-04-09 Nvidia Corporation System and method for configurable digital communication
US8412872B1 (en) 2005-12-12 2013-04-02 Nvidia Corporation Configurable GPU and method for graphics processing using a configurable GPU
US8724483B2 (en) 2007-10-22 2014-05-13 Nvidia Corporation Loopback configuration for bi-directional interfaces
US8687639B2 (en) * 2009-06-04 2014-04-01 Nvidia Corporation Method and system for ordering posted packets and non-posted packets transfer
US9176909B2 (en) 2009-12-11 2015-11-03 Nvidia Corporation Aggregating unoccupied PCI-e links to provide greater bandwidth
US9331869B2 (en) * 2010-03-04 2016-05-03 Nvidia Corporation Input/output request packet handling techniques by a device specific kernel mode driver
US9330031B2 (en) 2011-12-09 2016-05-03 Nvidia Corporation System and method for calibration of serial links using a serial-to-parallel loopback

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5645591A (en) 1990-05-29 1997-07-08 Stryker Corporation Synthetic bone matrix
HUT64565A (en) * 1990-12-13 1994-01-28 Genentech Inc Method for producing compounds and preparatives inhibiting resorption of bones
JP3351525B2 (ja) 1991-06-21 2002-11-25 ジェネティックス・インスティテュート・インコーポレイテッド 骨形成性蛋白医薬処方物
WO1993020859A1 (en) 1992-04-20 1993-10-28 Board Of Regents Of The University Of Washington Sustained release compositions for delivery of growth factors
CA2093836A1 (en) 1992-04-24 1993-10-25 Wayne Gombotz Biodegradable tgf-.beta. delivery system for bone regeneration
NO940913L (no) 1993-03-26 1994-09-27 Bristol Myers Squibb Co Preparater for kontrollert frigivelse av biologisk aktiv TGF-
WO1994024153A1 (en) 1993-04-08 1994-10-27 Ciba-Geigy Ag Cyclic compounds and compositions which inhibit bone resorption
JP2000502078A (ja) * 1995-12-09 2000-02-22 ベーリンガー マンハイム ゲゼルシャフト ミット ベシュレンクテル ハフツング 擬似アルギニン特性を有する３―アミノエチル―ｎ―アミジノ―２，５―ジヒドロピロール誘導体

Also Published As

Publication number Publication date
AU9439398A (en) 1999-03-29
CA2301969A1 (en) 1999-03-18
EP1009770A1 (en) 2000-06-21
JP2001515919A (ja) 2001-09-25
CN1269806A (zh) 2000-10-11
ZA988095B (en) 2000-03-22
TR200000598T2 (tr) 2000-07-21
BR9812056A (pt) 2000-09-26
US6429288B1 (en) 2002-08-06
KR20010023656A (ko) 2001-03-26
WO1999012970A1 (en) 1999-03-18
EP0902036A1 (en) 1999-03-17

Similar Documents

Publication Publication Date Title
AR013462A1 (es) Nuevos peptidomimeticos para el tratamiento de trastornos oseos, metodos para su produccion y drogas que contienen estos compuestos
CO4810373A1 (es) Compuestos azapoliciclicos condensados con arilo
UY27357A1 (es) Nuevos agentes antidiabéticos .
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
CO5550421A2 (es) Derivados de indol utiles para el tratamiento de enfermeda- des
AR039789A1 (es) Pirazolopiridinas sustituidas con carbamato
PA8432901A1 (es) Compuestos de piridilpirrol
AR034268A1 (es) Compuestos derivados de piperidina, su uso en preparacion de medicamentos, composicion farmaceutica, metodo de tratamiento y proceso para su preparacion
ECSP034831A (es) Derivados sustituidos de la 2-piridina ciclohexano-1,4-diamina
AR030541A1 (es) Acidos aminopropilfosfinicos, su utilizacion para la manufactura de medicamentos, y formulacion farmaceutica
ES2571779T3 (es) Inhibidores de cinasa a base de nicotinamida
AR044650A1 (es) Derivados de tiofeno - pirimidinona y su uso en la terapia de enfermedades que requieren la inhibicion de la enzima 17b-hidroxiesteroide-dehidrogenasa.
AR024390A1 (es) Nuevos compuestos
AR013079A1 (es) Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios
AR034120A1 (es) Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico
BRPI0312882B8 (pt) derivados de pleuromutilina e composição farmacêutica
AR063925A1 (es) Antibacteriales 5-hidroximetil -oxazolidin-2-ona composicion farmaceutica que los comprende y su uso para tratar o prevenir infecciones bacterianas
CR10974A (es) Inhibidores de carboxipeptidasa b plasmatica (divisional)
AR007088A1 (es) 2,4-diaminopirimidinas sustituidas, compuestos intermedios utilizados en su preparacion, procedimiento para la preparacion de dichas 2,4-diaminopirimidinas sustituidas, medicamentos que las contienen y empleos de dichas pirimidinas
UY26298A1 (es) "derivados de bencimidazol sustituidos con aminocarbonilo, procedimientos para su preparación y su utilización como medicamentos."
PE20021016A1 (es) Conjugados de pregabalina-lactosa
AR027578A1 (es) Derivados de indano
ES2051954T3 (es) 2-aminotiazoles substituidos.
AR050260A1 (es) Derivados de diarilmetilpiperazinas, su preparacion y su utilizacion
UY27324A1 (es) Nuevas sales de napsilato i

Legal Events

Date Code Title Description
FB Suspension of granting procedure